# Arrinex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arrinex

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.arrinex.com
- Total disclosed funding: $2.5M
- Latest round: Series A (Jun 29, 2016)
- Investors on record: 1

## About

Arrinex, Inc. is a medical device company focused on developing innovative solutions for nasal and sinus health, specializing in technology that enhances patient care and treatment outcomes in these areas.Arrinex, Inc. specializes in advanced medical devices targeting nasal and sinus health. Founded in 2013, the company is headquartered in Menlo Park, US. It raised USD 2.50 mn in its Series A round in February 2019, with 7 Gate Ventures as one of the investors. The company has completed 2 deals to date, and its current valuation stands at USD 18.60 mn. The company has not undergone any notable pivots or changes in business operations since its founding.Arrinex, Inc. offers a range of medical devices designed to address specific needs in the nasal and sinus health sectors. Their core products integrate advanced technology to improve treatment efficacy and patient experience. These specialized solutions cater to healthcare providers who require reliable tools to assist in complex procedures, ensuring operational efficiency and improved patient outcomes. The company operates primarily within North America, Europe, and parts of Asia-Pacific, serving a diverse clientele that includes both small practices and large medical institutions.The company’s revenue model is structured around B2B transactions, with clients typically engaging through annual contracts for its flagship medical devices. These contracts ensure access to a comprehensive package that includes product support and updates, tailored to meet specific client needs. The pricing is competitively positioned to provide a substantial return on investment through enhancements in operational efficiency. This transactional framework promotes long-term relationships, allowing Arrinex to maintain a steady revenue stream through recurring contracts and additional services as new devices are introduced.Looking ahead, Arrinex, Inc. aims to expand its product offerings in the nasal and sinus health markets, utilizing its latest funding to accelerate research and development of new devices. The company plans to launch innovative solutions designed to optimize treatment efficiency, with specific release dates to be announced as development progresses. Additionally, Arrinex is targeting expansion into new geographic markets, particularly in Europe and Asia-Pacific, within the next two years. The recent acquisition by Stryker Corporation in February 2019 will support these initiatives, providing additional resources and expertise to enhance their growth strategies.

## Funding rounds

- Series A, Jun 29, 2016, $2.5M — 7 Gate Ventures

## Investors

- 7 Gate Ventures (https://capitalatlas.ai/funds/7-gate-ventures) — Series A